HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arbutus Biopharma (NASDAQ:ABUS), maintaining a price target of $6.
September 12, 2023 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma's stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $6.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $6 indicates the firm's confidence in the stock's potential to reach this price, which could lead to an increase in investor interest and potentially a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100